Filing Analysis
aTyr Pharma received a notification from Nasdaq granting an additional 180-day extension until November 30, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share. The company failed to meet the initial compliance deadline of June 2, 2026.
🚩 Red Flags
- Failure to regain compliance by the initial 180-day deadline.
- Explicit mention of a potential reverse stock split to artificially inflate share price for compliance.
- Risk of delisting if compliance is not met by November 30, 2026.
📋 Key Facts
- The company received a deficiency notice on December 4, 2025, because the bid price closed below $1.00 for 30 consecutive business days.
- The initial compliance deadline was June 2, 2026.
- Nasdaq granted an extension until November 30, 2026, to regain compliance.
- Compliance requires a minimum closing bid price of $1.00 for at least 10 consecutive business days.
- The company has explicitly notified Nasdaq of its intention to cure the deficiency via a reverse stock split if necessary.
aTyr Pharma filed an 8-K to furnish an investor presentation dated June 2026. The company intends to use these materials for meetings with investors, stockholders, and analysts.
📋 Key Facts
- The filing date is June 1, 2026.
- The company is providing a corporate presentation (Exhibit 99.1) for use at investor conferences and meetings.
- The materials are being 'furnished' rather than 'filed' under Section 18 of the Securities Exchange Act of 1934.
aTyr Pharma, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made through a standard Item 2.02 filing, furnishing a press release as an exhibit.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 15, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
aTyr Pharma announced a significant pivot in its clinical development strategy for efzofitimod following a Type C meeting with the FDA. The company will initiate a new Phase 3 study with a narrowed patient population, increased dosing frequency, and enhanced safety monitoring for anti-synthetase syndrome.
🚩 Red Flags
- The requirement for a new Phase 3 study indicates that previous trial data (EFZO-FIT) was insufficient for an immediate NDA filing.
- The FDA mandated enhanced safety surveillance for the potential development of anti-synthetase syndrome, suggesting a specific safety concern.
- The company is narrowing its target patient population to a subset (restrictive lung disease) based on post-hoc analysis of 44 patients from a previous study.
📋 Key Facts
- Preliminary cash, cash equivalents, and investments totaled approximately $68.3 million as of March 31, 2026.
- The company plans to submit a new Investigational New Drug (IND) application in June 2026 for a Phase 3 study in pulmonary sarcoidosis.
- The new Phase 3 trial will target approximately 372 patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease (FVC ≤ 80%).
- Dosing frequency for the 5.0 mg/kg cohort will increase from once every four weeks to once every three weeks.
- The primary endpoint is the change from baseline in Forced Vital Capacity (FVC) at week 48.
aTyr Pharma, Inc. announced its financial results for the fiscal year ended December 31, 2025, through a press release issued on March 5, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1 to the filing.
- The filing was signed by Jill M. Broadfoot, Chief Financial Officer.